According to HealthWorX, IRS Memoranda Make Tax-Engineered Section 105(b) Programs Too Risky to Trust

HealthWorX warned that tax-engineered Section 105(b) employer healthcare reimbursement programs may create tax-reporting, withholding, FICA and FUTA liabilities when payments are not tied to actual unreimbursed medical expenses. The company cited three IRS Chief Counsel memoranda—201622031, 201719025 and 202323006—as consistent warnings that cash-like wellness and indemnity payments can constitute taxable wages. HealthWorX positioned its nonprofit-third-party administrator model as a compliance-focused alternative and said it had successfully undergone a U.S. Department of Labor audit.

Analysis

This is a marketing-led compliance warning rather than a new IRS enforcement action, so the near-term listed-equity read-through is limited. The more relevant mechanism is that aggressive reimbursement/wellness structures become a contingent liability for sponsoring employers: payroll-tax remediation, amended filings, penalties, and employee-relations costs can turn an apparent benefits-cost saving into a multi-year expense. The risk is concentrated among private benefit administrators and brokers whose economics depend on monetizing tax arbitrage, not diversified insurers or managed-care companies.

Over 1-3 months, the actionable catalyst would be evidence of examinations, promoter settlements, or IRS guidance that converts the cited interpretive posture into an enforcement priority. That could redirect employer demand toward fully insured supplemental products and conventional self-funded plan administration, modestly benefiting scaled compliance vendors such as ADP and PAYX at the margin, but the revenue contribution is unlikely to be material without verified adoption data. UNH, CVS, CI and ELV should not be treated as direct beneficiaries; their benefit-administration businesses are too diversified for this item alone to alter earnings expectations.

The contrarian view is that compliance-driven replacement may raise, rather than lower, employer healthcare spend if tax-optimized cash-like programs are discontinued without a cheaper care-delivery substitute. That would pressure smaller employers' benefit budgets and could reduce enrollment in voluntary products. Falsification of the regulatory-risk thesis would be formal IRS guidance narrowing the cited reasoning, or evidence that affected arrangements are structured around documented unreimbursed expenses and withstand audit scrutiny.

Key Decisions for Investors

• No directional equity trade on this release; treat it as an enforcement watch item rather than a catalyst for UNH, CVS, CI, ELV, AFL, ADP, or PAYX.
• Create a 1-3 month regulatory alert for IRS promoter investigations, settlements, or published guidance involving Section 105 reimbursement/wellness structures. Escalate only if named public brokers, administrators, or insurers disclose remediation reserves, client attrition, or payroll-tax exposure.
• If enforcement broadens, consider a relative long ADP / short a directly implicated small-cap benefits administrator or broker only after company-specific revenue exposure is disclosed. Require at least 15-20% downside to consensus EBITDA for the short leg and cap thesis risk if no enforcement action emerges within two quarters.
• For employer-service holdings, monitor quarterly commentary on voluntary-benefit enrollment and small-employer retention. A decline in enrollment alongside rising compliance costs would favor avoiding marginal voluntary-benefit exposure rather than buying large managed-care names.